- Conditions
- Anaplastic Large Cell Lymphoma, ALK-negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, +12 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
Clinical trial condition
Anaplastic Large Cell Lymphoma, ALK-negative
Explore clinical trials studying Anaplastic Large Cell Lymphoma, ALK-negative. Study availability and eligibility vary by location and protocol.
11 public trials
3 recruiting studies
Anaplastic Large Cell Lymphoma, ALK-negative trial results
Recruiting
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT06176690
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, +17 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
- Texas Children's Hospital Houston, Texas, United States
Recruiting
A Registry for People With T-cell Lymphoma
NCT05978141
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, +54 more
- Locations
-
- City of Hope Cancer Center (Data collection only) Duarte, California, United States
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) San Diego, California, United States
- University of California San Francisco (Data collection only) San Francisco, California, United States
- Stanford University Medical Center (Data collection only) Stanford, California, United States
Not yet recruiting
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
NCT07729397
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Diffuse Large B-Cell Lymphoma (DLBCL), +17 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
Active, not recruiting
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- M D Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT02978625
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- Keck Medical Center of USC Pasadena Pasadena, California, United States
Completed
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451
- Conditions
- ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
- Locations
-
- British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
- Peking University Third Hospital Beijing, Beijing Municipality, China
- Beijing Hospital Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital Beijing, Beijing Municipality, China
NCT02561273
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Enteropathy-Associated T-Cell Lymphoma, +21 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Stanford Cancer Institute Palo Alto, California, United States
- University of Colorado Cancer Center, Anschutz Cancer Pavilion Aurora, Colorado, United States
- Emory University/Winship Cancer Institute Atlanta, Georgia, United States
NCT01035463
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-negative, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
- Locations
-
- University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas, United States
- University of Nebraska Medical Center Omaha, Nebraska, United States
- Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
Completed
Risk Stratification of Nodal PTCL
NCT03040206
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Hemic and Lymphatic Diseases, +13 more
- Locations
-
- Chonbuk Nationla University Hospital Jeonju, South Korea